Zobrazeno 1 - 10
of 513
pro vyhledávání: '"Timothy J Price"'
Autor:
David L Chan, Katrin M Sjoquist, David Goldstein, Timothy J Price, Andrew J Martin, Yung-Jue Bang, Yoon-Koo Kang, Nick Pavlakis
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172307 (2017)
BACKGROUND:Studies of anti-angiogenic agents (AAs), combined with chemotherapy (chemo) or as monotherapy in metastatic oesophago-gastric cancer (mOGC), have reported mixed outcomes. We undertook systematic review and meta-analysis to determine their
Externí odkaz:
https://doaj.org/article/33d9c021ca5641268cd8fd7cd72c84ff
Autor:
Sarah M Bernhardt, Pallave Dasari, David Walsh, Amanda R Townsend, Timothy J Price, Wendy V Ingman
Publikováno v:
Frontiers in Oncology, Vol 6 (2016)
Clinics are increasingly adopting gene expression profiling to diagnose breast cancer subtype, providing an intrinsic, molecular portrait of the tumour. For example, the PAM50-based Prosigna test quantifies expression of 50 key genes to classify brea
Externí odkaz:
https://doaj.org/article/562affccf1e04f80bfe6e775ecd28c0a
Autor:
David L Chan, Nick Pavlakis, Jeremy Shapiro, Timothy J Price, Christos S Karapetis, Niall C Tebbutt, Eva Segelov
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138916 (2015)
Externí odkaz:
https://doaj.org/article/0d976c1ee1ce4862826486e35bfc456c
Autor:
David L Chan, Nick Pavlakis, Jeremy Shapiro, Timothy J Price, Christos S Karapetis, Niall C Tebbutt, Eva Segelov
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135599 (2015)
The EGFR inhibitors (EGFR-I) cetuximab and panitumumab and the angiogenesis inhibitors (AIs) bevacizumab and aflibercept have demonstrated varying efficacy in mCRC.To document the overall impact of specific chemotherapy regimens on the efficacy of ta
Externí odkaz:
https://doaj.org/article/3fc46901741e49769c514e2ab18e7512
Autor:
Maryam Nakhjavani, Eric Smith, Kenny Yeo, Yoko Tomita, Timothy J. Price, Andrea Yool, Amanda R. Townsend, Jennifer E. Hardingham
Publikováno v:
Journal of Ginseng Research, Vol 48, Iss 2, Pp 171-180 (2024)
Background: Epimers of ginsenoside Rg3 (Rg3) have a low bioavailability and are prone to deglycosylation, which produces epimers of ginsenoside Rh2 (S–Rh2 and R–Rh2) and protopanaxadiol (S-PPD and R-PPD). The aim of this study was to compare the
Externí odkaz:
https://doaj.org/article/d3219bb4238843c5b88fc8508204b692
Autor:
Sarah M. Bernhardt, Pallave Dasari, Joseph Wrin, Wendy Raymond, Suzanne Edwards, David Walsh, Lucy Woolford, Amanda R. Townsend, Timothy J. Price, Wendy V. Ingman
Publikováno v:
Breast, Vol 68, Iss , Pp 240-241 (2023)
Externí odkaz:
https://doaj.org/article/1e4dd636d1914e2a8d2aef65a916d52e
Autor:
Eric Smith, Yoko Tomita, Helen M. Palethorpe, Stuart Howell, Maryam Nakhjavani, Amanda R. Townsend, Timothy J. Price, Joanne P. Young, Jennifer E. Hardingham
Publikováno v:
Epigenetics, Vol 14, Iss 2, Pp 158-170 (2019)
Aquaporin-1 (AQP1) is a homo-tetrameric transmembrane protein that facilitates rapid movement of water and ions across cell membranes. The clinical significance of AQP1 expression in colorectal carcinoma (CRC) is controversial. The aim of this study
Externí odkaz:
https://doaj.org/article/725a0bffb049495ba0120c85830ed219
Autor:
Daniel Shepshelovich, Amanda R. Townsend, Osvaldo Espin‐Garcia, Lidija Latifovic, Chris J. O’Callaghan, Derek J. Jonker, Dongsheng Tu, Eric Chen, Eric Morgen, Timothy J. Price, Jeremy Shapiro, Lillian L. Siu, Michiaki Kubo, Alexander Dobrovic, Mark J. Ratain, Wei Xu, Taisei Mushiroda, Geoffrey Liu
Publikováno v:
Cancer Medicine, Vol 7, Iss 11, Pp 5478-5487 (2018)
Abstract Background Two germ line Fc‐γ receptor (FCGR) polymorphisms, rs1801274 [FCGR2A; His(H)131Arg(R)] and rs396991 [FCGR3A; Phe(F)158Val(V)], produce altered proteins through amino acid substitutions. We previously reported that the FCGR2A H/H
Externí odkaz:
https://doaj.org/article/628a67c545864055ae4f182dd106b2be
Autor:
Tiffany Foo, David Goldstein, Eva Segelov, Jeremy Shapiro, Nick Pavlakis, Jayesh Desai, Desmond Yip, John Zalcberg, Timothy J. Price, Adnan Nagrial, Lorraine Chantrill, Matt Burge, Christos S. Karapetis, Niall Tebbutt, Amitesh C. Roy
Publikováno v:
Targeted Oncology. 17:95-110
Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal tract mesenchymal tumours. Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced GIST. Imatinib was the first TKI to gain approval as management for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6af20c25575c0a9d5ac48c45928a2fc
https://doi.org/10.1007/s11523-022-00869-y
https://doi.org/10.1007/s11523-022-00869-y
Autor:
Marwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, Tae Won Kim, Pamela N Munster, John C Krauss, Gerald S Falchook, Sae-Won Han, Volker Heinemann, Kei Muro, John H Strickler, David S Hong, Crystal S Denlinger, Gustavo Girotto, Myung-Ah Lee, Haby Henary, Qui Tran, Joseph K Park, Gataree Ngarmchamnanrith, Hans Prenen, Timothy J Price
Publikováno v:
The lancet oncology
Background Sotorasib, a specific, irreversible KRAS(G12C) protein inhibitor, has shown monotherapy clinical activity in KRAS(G12C)-mutated solid tumours, including colorectal cancer, in the CodeBreaK100 phase 1 trial. We aimed to investigate the acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01c8895175769c7fb8e15873f4aba538
https://doi.org/10.1016/s1470-2045(21)00605-7
https://doi.org/10.1016/s1470-2045(21)00605-7